PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation

Professor  Heikki Joensuu, M.D., Ph.D., has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation as of  1 December 2017.
 
Heikki Joensuu (born 1956) is a Finnish oncologist and cancer researcher. Joensuu joins Orion from the Comprehensive Cancer Center, Helsinki University Hospital, where he worked as the Research Director from 2015 to 2017. Prior to that, he was Research Professor of the Academy of Finland  from 2010 to 2014. At present he is the Director of the Laboratory of Molecular Oncology, Biomedicum, Helsinki, and his research group is a part of a Center of Excellence of the Academy of Finland. 
 
The main topics of his clinical and translational research have been breast cancer and gastrointestinal stromal tumour (GIST). He has received several national and international science awards, including the Matti Äyräpää Prize in 2012 (the most prestigious medical prize in Finland).
 
The recruitment  of  Professor Joensuu is related  to Orion’s renewed Research and  Development organization (into effect  on 1 October 2017) in which  the prior Research and Development  processes are replaced by parallel Therapy Area Management processes with end-to-end responsibility from new ideas through registration.  Oncology is one of Orion’s main focus areas in the pharmaceutical  Research and Development. Professor Joensuu will continue working at the Comprehensive Cancer Center Helsinki as  a scientific  advisor.
                                                         
Christer Nordstedt, MD., PhD. Senior Vice President for Orion’s Research and Development says:
“I am very excited to become a colleague of  Professor Heikki Joensuu and I warmly welcome him to the Orion team. This appointment is an excellent step to further the co-operation of Helsinki University Hospital and Orion and boosts our  relationship. I am also happy that such a top researcher from academic society joins Orion – in past few years several of our  colleagues have left  the company to the top positions in the universities and public sector. This cross fertilization between the public and private sectors is very likely to be beneficial for the scientific and public communities.”
 
Heikki Joensuu, M.D., professor says:
“During my career as a doctor and a scientist I have been in a priviledged position to witness the great improvements in the care of cancer patients over the last decades. The results obtained with the novel targeted drugs can sometimes be described as miraculous, and they are frequently a great joy to the patients and their families. My new position at Orion allows me to maintain and deepen my research focus, which is to develop such treatments for cancer patients wherever they live. I hope that my long background in the academia will help in the initiation of new research projects between Orion and the academia. Such collaboration will likely benefit all stakeholders, including the society and, most importantly, the patients.”   
 
Johanna Mattson, M.D., PhD., Director of the Helsinki University Hospital Comprehensive Cancer Center (CCC) says:
” I believe that in this collaboration model Heikki Joensuu’s exceptional expertise can maximally benefit the ultimate goal of better cancer treatments for patients. His clinical and translational scientific projects will continue as he will work as a scientific advisor at the CCC.  We have recruited new  senior scientists to continue these projects as well as to start new ones.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026